长春金赛药业有限责任公司

Chinese biopharmaceutical company founded in 1996, a controlled subsidiary of the state-backed listed company Changchun High & New Technology Industry (000661), with its administrative headquarters in Changchun, Jilin and operating headquarters in Shanghai. An innovation-driven company covering the full chain from research through manufacturing to sales, with revenue above ten billion yuan and close to ten thousand staff, it is China's largest genetically engineered pharmaceutical company and Asia's largest producer of recombinant human growth hormone, and serves as China's demonstration centre for genetically engineered drug quality management and a national incubation base for genetically engineered new drugs. Its pipeline covers endocrine and metabolic disease, oncology and immunology, with commercial products in gout, assisted reproduction, gynaecological infection, cancer cachexia, paediatric respiratory disease and children's growth.